| Name | Title | Contact Details |
|---|
Prosetta Biosciences, Inc. is an 11-year old biotechnology company developing novel small-molecule antiviral therapeutics based on over 25 years of basic research on the Cell-Free Protein Synthesizing Systems (CFPSS) by scientists at the University of California, San Francisco and the University of Washington, Seattle. The incorporation of the CFPSS in our drug discovery platform, has lead to the identification of small molecules which disrupt or alter the key protein-protein interactions involved with the assembly of viral capsids (the protein shell that protects the DNA or RNA genome of a virus). Prosetta has successfully produced highly potent compounds which display activity against multiple strains of many viral families including lead series of molecules that are effective antiviral agents against Influenza, HIV and HCV.
Cleveland Diagnostics is developing a breakthrough technology to discover a new class of diagnostics tests with high sensitivity and specificity for many cancers – early on, when cancer is still curable.
Elastrin Therapeutics is a South Carolina-based biotech developing novel therapies to reverse cardiovascular disease. Its underlying technology was developed by Dr. Naren Vyavahare during the last 20 years at Clemson University, in collaboration with Dr. Charles Rice.
PreciThera, Inc. is a biotechnology company committed to the development of therapies for rare bone diseases using the combined application of computational technology and a deep understanding of disease pathology.
Libra Therapeutics is focused on developing novel disease-modifying therapeutics that can restore the cellular balance disrupted in neurodegenerative diseases.